StocksMedium•29 September 2026•
1 min read
UniQure Shares Plunge 48% Following Huntington's Disease Trial Results
Key Facts
1UniQure shares plunged 48% after its experimental gene therapy AMT-130 failed to reach statistical significance in a recent study.
2The company insists there is still a path to regulatory approval despite the disappointing trial results.
UniQure shares plunged 48% after its experimental gene therapy AMT-130 failed to reach statistical significance in a recent study. Barron's reported that the massive sell-off followed clinical trial data for the Huntington's disease treatment which failed to meet key statistical benchmarks.
The company insists there is still a path to regulatory approval despite the disappointing trial results observed on September 29, 2026. The market reaction highlights the significant impact of clinical trial outcomes on the valuation of biotech firms specializing in gene therapy.